At the JPMorgan Healthcare Conference, Genmab emphasized a long-term growth strategy centered on disciplined R&D investment ...

Andy Timmerwilke is a Managing Director at Merrill (Bank of America) in Chicago advising high‑net‑worth families, executives, ...

Novavax entered the 2026 J.P. Morgan Healthcare Conference positioning itself as a partner-driven company focused on ...

AbbVie is focused on pipeline expansion and diversification to address the upcoming patent cliff, with significant financial ...

Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, ...

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen ...

According to Van de Winkel, Genmab is set to enter 2026 with an improved balanced across its earnings, mixing royalties and ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts ...

Hayley Burgess SVP, Inovalon, talks about how pharmacies preserve efficiency while strengthening patient care by using ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

Michael O'Rourke, CEO of Re-Vana Therapeutics, touches on Re-Vana's transition from an academic spinout to a fully ...